Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.66 |
| ▸ | PKN1 | Q16512 | 4/20 | 0.66 |
| ▸ | PKN2 | Q16513 | 4/20 | 0.66 |
| ▸ | HPGD | P15428 | 3/20 | 0.65 |
| ▸ | RHEB | Q15382 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | GUSB | P08236 | 1/20 | 0.55 |
| ▸ | SCD | O00767 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.50 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ridinilazole SCHEMBL29379856 | 1.00 | ALDH1A1 (0.66) | ALDH1A1KDM4EPKN1PKN2HPGD | |
| Ridinilazole SCHEMBL17867397 | 0.93 | NPC1 (0.65) | ALDH1A1KDM4EPKN1PKN2HPGD | |
| SCHEMBL16498509 | 0.92 | KDM4E (0.57) | ALDH1A1KDM4EPKN1PKN2HPGD | |
| SCHEMBL6263502 | 0.91 | ALDH1A1 (0.58) | ALDH1A1KDM4EPKN1PKN2HPGD | |
| SCHEMBL22906080 | 0.91 | ALDH1A1 (0.58) | ALDH1A1KDM4EPKN1PKN2HPGD | |
| SCHEMBL14834116 | 0.89 | KDM4E (0.54) | ALDH1A1KDM4EPKN1PKN2HPGD | |
| SCHEMBL16499476 | 0.88 | ALDH1A1 (0.65) | ALDH1A1KDM4EPKN1PKN2HPGD | |
| SCHEMBL16499516 | 0.88 | ALDH1A1 (0.53) | ALDH1A1KDM4EPKN1PKN2HPGD | |
| SCHEMBL16498482 | 0.88 | ALDH1A1 (0.53) | ALDH1A1KDM4EPKN1PKN2HPGD | |
| SCHEMBL19994448 | 0.87 | ALDH1A1 (0.59) | ALDH1A1KDM4EPKN1PKN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9763925-B2 | Antibacterial compounds | SUMMIT THERAPEUTICS PLC (GB) | 2017-09-19 | — | — | US | claimed |
| US-20160184283-A1 | ANTIBACTERIAL COMPOUNDS | SUMMIT (OXFORD) LIMITED (GB) | 2016-06-30 | — | — | US | claimed |
| EP-2907813-B1 | Antibacterial pharmaceutical compositions | SUMMIT THERAPEUTICS PLC (GB) | 2016-04-27 | — | — | EP | claimed |
| US-9314456-B2 | Antibacterial compounds | SUMMIT THERAPEUTICS PLC (GB) | 2016-04-19 | — | — | US | claimed |
| EP-2907813-A1 | Antibacterial Compound | Summit Corporation Plc (GB) | 2015-08-19 | — | — | EP | claimed |
| US-20150150861-A1 | ANTIBACTERIAL COMPOUNDS | SUMMIT (OXFORD) LIMITED (GB) | 2015-06-04 | — | — | US | claimed |
| US-8975416-B2 | Antibacterial compounds | SUMMIT CORPORATION PLC (GB) | 2015-03-10 | — | — | US | claimed |
| EP-2373631-B1 | ANTIBACTERIAL COMPOUNDS | SUMMIT CORP PLC (GB) | 2015-02-25 | — | — | EP | claimed |
| EP-2373631-A2 | ANTIBACTERIAL COMPOUNDS | Summit Corporation Plc (GB) | 2011-10-12 | — | — | EP | claimed |
| WO-2010063996-A2 | ANTIBACTERIAL COMPOUNDS | SUMMIT CORPORATION PLC (GB) | 2010-06-10 | — | — | WO | claimed |
| US-12318487-B2 | Solid tablet dosage form of ridinilazole | SUMMIT (OXFORD) LIMITED (GB) | 2025-06-03 | — | — | US | disclosed |
| US-12318487-B2 | Solid tablet dosage form of ridinilazole | SUMMIT (OXFORD) LIMITED (GB) | 2025-06-03 | — | — | US | disclosed |
| WO-2024079245-A1 | RIDINILAZOLE FOR TREATING CLOSTRIDIUM DIFFICILE | SUMMIT (OXFORD) LIMITED (GB) | 2024-04-18 | — | — | WO | disclosed |
| EP-4277604-A1 | SOLID TABLET DOSAGE FORM OF RIDINILAZOLE | Summit (Oxford) Limited (GB) | 2023-11-22 | — | — | EP | disclosed |
| EP-4277604-A1 | SOLID TABLET DOSAGE FORM OF RIDINILAZOLE | Summit (Oxford) Limited (GB) | 2023-11-22 | — | — | EP | disclosed |
| EP-2907813-A1 | Antibacterial Compound | Summit Corporation Plc (GB) | 2015-08-19 | — | — | EP | disclosed |
| US-20150150861-A1 | ANTIBACTERIAL COMPOUNDS | SUMMIT (OXFORD) LIMITED (GB) | 2015-06-04 | — | — | US | disclosed |
| US-8975416-B2 | Antibacterial compounds | SUMMIT CORPORATION PLC (GB) | 2015-03-10 | — | — | US | disclosed |
| EP-2373631-B1 | ANTIBACTERIAL COMPOUNDS | SUMMIT CORP PLC (GB) | 2015-02-25 | — | — | EP | disclosed |
| US-20120020950-A1 | ANTIBACTERIAL COMPOUNDS | SUMMIT CORPORATION PLC | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160184283-A1 | ANTIBACTERIAL COMPOUNDS | MRPL21, RPN2, ALPI | ALDH1A1 1088/4885KDM4E 4769/4885PKN1 3660/4885 |
| US-12318487-B2 | Solid tablet dosage form of ridinilazole | CYP3A5, CYP3A4, CYP3A7 | ALDH1A1 357/4885KDM4E 3535/4885PKN1 1391/4885 |
| US-20120020950-A1 | ANTIBACTERIAL COMPOUNDS | RPN2, MRPL21, ALPI | ALDH1A1 1135/4885KDM4E 4763/4885PKN1 3621/4885 |
| US-20150150861-A1 | ANTIBACTERIAL COMPOUNDS | MRPL21, RPN2, ALPI | ALDH1A1 1088/4885KDM4E 4769/4885PKN1 3660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.